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Epidemiology and risk factors of candidemia due to 
Candida parapsilosis in an intensive care unit
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ABSTRACT 
We analyzed the clinical features and risk factors of candidemia due to C. parapsilosis 
(n=104) in the intensive care unit of a tertiary hospital over six years. This was a 
monocentric, retrospective study of candidemia, conducted from January 2013 to March 
2019. Epidemiological characteristics, clinical features, invasive procedures, laboratory 
data and outcomes of 267 patients with candidemia were analyzed to determine risk factors 
of candidemia due to C. parapsilosis. Sixty-three cases of C. albicans and 204 cases of 
non-C. albicans Candida (NCAC) species were included, the latter was composed of 104 cases 
of C.  parapsilosis and 100 cases of non-C.  albicans species (46 cases of C.  tropicalis, 
22 cases of C. glabrata, 23 cases of C. guilliermondii, 5 cases of C. krusei and 4 cases of 
C. lusitaniae), suggesting that C. parapsilosis was the predominant Candida species isolated 
from cases of candidemia. A binary multivariate logistic regression analysis showed that 
APACHE II scores, central venous catheterization and the use of broad-spectrum antibiotics 
were closely related to C. parapsilosis candidemia, with OR values of 1.159, 3.913 and 2.217, 
respectively. In conclusion, we found that C. parapsilosis was the main pathogen among the 
NCAC candidemia in the ICU patients. APACHE II scores, central venous catheterization 
and the use of broad-spectrum antibiotics were independent risk factors for the occurrence 
of C. parapsilosis candidemia, which may provide data to support the early introduction of 
anti-fungal therapy. 
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INTRODUCTION
Candida albicans (C.  albicans) is the most common known pathogen of 
invasive infections in adult non-neutropenic Intensive Care Unit (ICU) patients, 
causing roughly 70% of candidemia1,2, increasing the length of stay in either the 
ICU or the hospital, with an attributable mortality rate varying from 35% to 50%3,4. 
However, in recent years, there has been a gradually increase in the incidence of 
candidemia caused by non-C. albicans species5-7, especially of Candida parapsilosis 
(C.  parapsilosis)8-10, which is reported as the second most commonly isolated 
Candida spp. from blood cultures (Figure 1), even outranking C.  albicans and 
becoming the most important pathogens in candidemia cases11,12. More and more 
attention has been paid on its clinical features and pathogenesis by healthcare 
workers and experts. 
Some studies suggest that the increasing incidence of C. parapsilosis candidemia 
is related to the characteristics of the treatment regimen (such as long-term 
hospitalization), microorganism-related properties (its specific affinity with the 
surface of intravascular devices and certain prosthetic materials or plastics to form 
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biofilms), and high glucose and fat environments favoring 
the gastrointestinal colonization and transmission5,13-16. 
Adhesion and biofilm formation are very important factors 
for C. parapsilosis indwelling on devices which appear to 
be the predominant route of infection15. The majority of 
patients with C. parapsilosis candidemia reported so far 
presented with underlying co-morbidities that required the 
use of intravenous indwelling catheters and total parenteral 
nutrition16. However, most of the studies were frequently 
small in size and covered a short period of time. Because of 
the increasing trend and the importance of C. parapsilosis to 
healthcare, our study intended to determine the risk factors 
of C. parapsilosis candidemia compared with those due 
to C. albicans and other non-C. albicans species in ICU 
wards of a large tertiary hospital in Hubei province, China. 
MATERIALS AND METHODS
Study design
Clinical data were collected from patients with 
candidemia in ICU wards of a large tertiary hospital in 
Hubei, China, from January 2013 to March 2019. A total 
of 267 patients with candidemia were enrolled. The study 
protocol was reviewed and approved by the Committee for 
the Protection of Human Subjects at the Renmin Hospital 
of Wuhan University (RHWU).
Definitions
All cases met the diagnostic criteria of the Centers 
for Disease Control and Prevention (CDC)17. They were 
reported by the Department of Clinical Microbiology 
Laboratory, and the species causing candidemia were 
identified using the IVD MALDI Biotyper mass 
spectrometry (Bruker, Germany). Inclusion criteria 
were: (1) A patient who developed signs or symptoms of 
blood stream infection (BSI) > 48 h after ICU admission. 
(2) Laboratory microbiological examination with at least 
one positive blood culture to Candida spp. and samples to 
perform blood cultures drawn from either a central venous 
catheter or a peripheral vein/artery. If the same patient 
had multiple episodes of candidemia during the study 
period, only the first episode of candidemia was included. 
(3)  Presence of other signs or symptoms suggestive of 
systemic infections: fever > 38 °C, chills, hypotension, 
multiple organ dysfunction, etc. Exclusion criteria: (1) Age 
< 18 years; (2) Suspected candidemia occurred before ICU 
admission; (3) Transfer, death, or central venous catheter 
duration < 48 h after ICU admission.
Data collection for risk factors
In our study, 267 candidemia patients hospitalized in 
the ICU were included. All patients were retrospectively 
assessed for risk factors associated with candidemia. For 
all the identified patients, we performed a detailed medical 
record review and retrieved data from the electronic 
medical records and reports from the RHWU Clinical 
Microbiology Laboratory. Briefly, we need to collect 
demographic data, clinical data such as host factors, 
medical interventions and laboratory data. Host factors 
included age, gender, underlying diseases (comorbidities) 
such as lung disease, circulatory system disease, neoplastic 
Figure 1 - Summary of 2014 data of CHIF-NET. The graphic indicated the incidence of different Candida species from blood in 5 
years (2010-2014) published in China-Hospital-Invasive-Fungal-Surveillance-NET.
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disease, kidney disease, liver disease, etc., the APACHE II 
Score (Acute physiology and chronic health evaluation) 
within 24 h after ICU admission, ICU length of stay, and 
outcome. Retrieved medical interventions included total 
parenteral nutrition (TPN), mechanical ventilation (MV), 
prior use of medications (broad-spectrum antibiotics, 
hormones, immunosuppressants, etc.), abdominal surgeries, 
intravascular catheterization location (jugular, subclavian 
and femoral) and duration (> 5 days) considering the risks 
of infections and the time required by Candida spp. to 
adhere, colonize and form mature biofilms. Laboratory data 
included the patients’ immune status (presence or absence 
of neutropenia), G test results, coinfections with bacteria 
and different organs disfunctions.
Statistical analysis
Categorical variables were compared by the chi square 
test or the Fisher exact test (SPSS Version 20.0, IBM, 
Armonk, NY, USA). Odds ratios (OR) and 95% confidence 
intervals (CI) were calculated to evaluate the strength of 
selected associations. Continuous variables were compared 
using the Wilcoxon rank sum test. A two-tailed p-value of 
< 0.05 was considered significant. A multivariate logistic 
regression analysis was performed to identify associations 
between variables and risk factors to develop candidemia 
due to C. parapsilosis compared to other Candida species. 
Besides the multi-collinearity among some variables in the 
multivariate analysis, variables with a univariate p-value 
< 0.1 were considered for the inclusion in the multivariate 
model.
RESULTS
During the 6-year study period 2013-2019, 267 
candidemia patients were enrolled at RHWU (Figure 2). All 
the included patients were divided into groups: C. albicans, 
C. parapsilosis and other non-C. albicans species group.
Species distribution
Among the detected 267 patients with candidemia, 
63 (23.6%) were caused by C. albicans, 104 (39.0%) by 
C. parapsilosis and 100 (37.4%) by other non-C. albicans 
species, include 46 (17.2%) cases of C.  tropicalis, 
22 (8.2%) cases of C.  glabrata, 23 (8.6%) cases of 
C.  guilliermondii, 5 (1.9%) cases of C.  krusei and 4 
(1.5%) cases of C. lusitaniae (Table 1). The total number 
of isolates of non-C. albicans species was 204 (76.4%). 
The most common isolated species were C. parapsilosis, 
followed by C. albicans, C. tropicalis, C. guilliermondii, 
C. glabrata and C. krusei. 


















Figure 2 - Flow diagram. The graphic described the diagnostic criteria, inclusion criteria and exclusion criteria, how many patients 
were included and explained why.
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Demographic characteristics of patients with different 
species of candidemia are shown in Table 2. One hundred and 
twenty one (45.3%) patients were male and the mean age of 
patients was 58.12 ± 16.51 years. In the C. albicans group, 
33 patients were male and 30 patients were female, the mean 
age was 61.41 ± 15.98 years, while in the non-C. albicans 
species group, 88 (33.0%) patients were male and 116 
(43.4%) patients were female, and the mean age was 57.11 
± 16.58 years. Regarding gender and age, no significant 
differences were found between patients with candidemia 
due to C. parapsilosis and other Candida species. 
To investigate the correlation between severity of illness 
and episodes of candidemia caused by C. parapsilosis, we 
found that the mean of APACHE II Scores in all groups was 
above 20. In the C. albicans group, the mean of APACHE 
II Score was 21.71±3.21; 25.85±6.08 in the C. parapsilosis 
group and 22.33±4.90 in the group of other non-C. albicans 
species. We found that the APACHE II Score of patients 
with C. parapsilosis candidemia episodes was higher than 
in both groups of C. albicans and other non-C. albicans 
species (p=0.000). These results are shown in Table 2. 
Relationship between the presence of underlying 
diseases (comorbidities) and episodes of candidemia 
caused by different Candida species
We investigated the presence of underlying diseases 
(comorbidities) and the main diagnosis of the enrolled ICU 
patients. There were 16 cases of type 2 diabetes, 14 cases of 
renal insufficiency, 20 patients with hypertension, 13 cases 
of heart disease, 10 cases of chronic obstructive pulmonary 
disease, 13 cases of cerebral ischemia, 3 cases of cirrhosis, 
3 cases of congenital heart disease, 8 cases of neoplastic 
disease, 2 cases of autoimmune disease and 35 cases of 
comorbidities involving more than 2 systems. There were 
no significant differences in the frequency of comorbidities 
and the major causes of ICU admission among groups 
of candidemia by C. albicans, C. parapsilosis and other 
non-C. albicans species. These results are shown in Table 2.
Relationship between the use of medical interventions 
and the presence of episodes of candidemia caused 
by different Candida species
Of the 267 patients, 124 (46.4%) cases were placed with 
a central venous catheter (double-lumen), of which 21 cases 
were in C. albicans group, 75 cases were in C. parapsilosis 
group, and 28 cases were in other non-C. albicans species 
group. Regarding the catheter location, there were 48 
cases of subclavian vein catheterization (six cases in 
C. albicans group, 32 cases in C. parapsilosis group, and 
10 cases in other groups), 35 cases of internal jugular vein 
catheterization (ten cases in C. albicans group, 16 cases 
in C. parapsilosis group, and nine cases in other groups), 
57 cases of femoral vein catheterization (nine cases in 
C.  albicans group, 34 cases in C.  parapsilosis group, 
Table 2 - Comparison of epidemiological characteristics of patients hospitalized in an intensive care unit presenting with infections 









Age (years) (Mean ± SD) 61.41±15.98 57.02±15.51 57.20±17.69 > 0.05
Gender (Male) 33 (52.4) 46 (44.2) 42 (42.0) > 0.05
Comorbidities 
Type 2 diabetes 
Renal insufficiency 
Hypertension 
Coronary heart disease 
COPD 
Cerebral ischemia  
Cirrhosis 
Congenital heart disease 
Neoplastic disease 
Autoimmune disease 






































APACHE II Score 21.71±3.21 25.85±6.08a 22.33±4.90 0.000
ICU length of stay (days) 14.38±8.05 14.13±7.50 12.98±7.73 > 0.05
Mortality 5 (7.9) 12 (11.5)a 8 (8.0) 0.046
*Values for all variables except age, APACHE II Scores and ICU-stay are given in percentages of patients; #All Candida species other 
than C. albicans or C. parapsilosis included 46 C. tropicalis, 22 C. glabrata, 23 C. guilliermondii, 5 C. krusei and 4 C. lusitaniae; 
SD = Standard deviation; APACHE = Acute Physiology and Chronic Health Evaluation; ICU = Intensive Care Unit; COPD = Chronic 
obstructive pulmonary disease; aP <0.05, significant difference between between C. parapsilosis and Others (C. parapsilosis vs 
Others). 
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14 cases in other groups), and eight cases of basilic vein 
catheterization (one case in C. albicans group, five cases in 
C. parapsilosis group, two cases in other groups). Among 
them, 24 patients had catheters in both, the jugular vein or 
the subclavian vein or the basilic vein and the femoral vein 
(four cases in C. albicans group, 13 cases in C. parapsilosis 
group, and seven cases in non-C. albicans species group). 
We found that the presence of central venous catheters, the 
CVC duration > 5 days and the catheterization locations 
in the subclavian and the femoral vein, were significant 
different between C. parapsilosis, C. albicans and the other 
non-C.  albicans species group (p=0.000; 0.024; 0.000; 
0.002). These results are shown in Table 3. 
It has been reported that total parenteral nutrition (TPN) 
is an important factor of biofilm formation. We examined 
the total parenteral nutrition > 3 days in the different 
Candida species groups and found that differences were 
significant between C. parapsilosis, C. albicans and other 
non-C. albicans species (p=0.000). These results are shown 
in Table 3. 
In respect to the prior risk factors (reported before the 
ICU hospitalization), we checked the use of broad-spectrum 
antibiotics in the different Candida species groups and 
found that there was a significant difference between 
C. albicans and other non-C. albicans species (p=0.000), 
also between C. albicans and C. parapsilosis (p=0.000). 
Considering the mechanical ventilation, there was a 
significant difference between C. parapsilosis, C. albicans 
and other non-C. albicans species (p=0.000; 0.046) groups. 
These results are shown in Table 3.
Comparison of laboratory data of different species 
causing candidemia
We investigated some important clinical parameters 
including neutropenia, positivity of the G test (1,3-β-D-
Glucan [BDG]) test. which is a fungal cell wall constituent 
used in the diagnosis of invasive fungal infections), the 
presence of multiple organ dysfunction syndrome (MODS) 
and coinfections. Through these comparisons, we found 
that there were no significant differences among groups 
of C. albicans, C. parapsilosis and other non-C. albicans 
species. These results are shown in Table 4.
Risk factors associated with C. parapsilosis candidemia
Relevant risk factors included in the analysis of 
C. parapsilosis bloodstream infections were gender, age, 
underlying diseases (comorbidities), the APACHE  II 
score, the ICU length of stay (days), mortality, use 
of broad-spectrum antibiotics, use of steroids and 
immunosuppressants, CVC placement and location, 
catheterization duration > 5 days, use of total parenteral 
nutrition (TPN) > 3 days, special medical interventions 
such as continuous renal replacement therapy (CRRT), 
mechanical ventilation, abdominal surgeries, clinical data 






Others# (n=100) 95% CI P
Broad-spectrum antibiotics 30 (47.6)a 76 (73.1) 73 (73.0) 0.338-0.554 0.000
Steroids 2 (3.2) 4 (3.8) 5 (5.0) - > 0.05
Immunosuppressants 0 (0.0) 0 (0.0) 1 (1.0) - -
Central venous catheter 21 (33.3) 75 (72.1)b 28 (28.0) 0.277-0.530 0.000
Internal jugular 10 (15.9) 16 (15.4) 9 (9.0) - > 0.05
Subclavian vein 6( 9.5) 32 (30.8)b 10 (10.0) 0.099-0.316 0.000
Femoral vein 9 (14.3) 34 (32.7)b 14 (14.0) 0.072-0.302 0.002
Basilic vein 1 (1.6) 5 (4.8)  2 (2.0) - > 0.05
CVC duration >5 days 14 (22.2) 45 (43.3)b 2 3(23.0) 0.019-0.271 0.024
Total parenteral nutrition >3 days 21 (33.3) 72 (69.2)b 42 (42.0) 0.140-0.405 0.000





Continuous renal replacement therapy 11 (17.5) 21 (20.2) 13 (13.0) - > 0.05
Abdominal surgeries 16 (25.4) 27 (26.0) 26 (26.0) - > 0.05
*Values for all variables are given in percentages of patients; #All Candida species other than C. albicans or C. parapsilosis included 
46 C. tropicalis, 22 C. glabrata, 23 C. guilliermondii, 5 C. krusei and 4 C. lusitaniae; CVC = Central venous catheter; aP<0.05, 
significant difference between C. albicans and other Candida species (C. albicans vs Others); bP<0.05, significant difference 
between C. parapsilosis and other Candida species (C. parapsilosis vs Others). 
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such as neutropenia, positivity of the G test, the multiple 
organ dysfunction syndrome (MODS), coinfections with 
other bacteria (mainly Gram-positive / negative bacteria). 
An univariate analysis was performed on the variables, 
searching for possible risk factors of C.  parapsilosis 
bloodstream infections. The results showed that the 
APACHE II Score, therapy with broad-spectrum antibiotics, 
the presence of a central venous catheter, catheterization 
locations and duration, total parenteral nutrition > 3 
days and mechanical ventilation were all risk factors for 
C.  parapsilosis bloodstream infection (p=0.000; 0.001; 
0.000; 0.003; 0.013; 0.009; 0.000; 0.029). Regarding 
to the ICU length of stay, CRRT treatment, abdominal 
surgeries, neutropenia, a positive G test, MODS and 
coinfections were not significantly related to the occurrence 
of C. parapsilosis bloodstream infections (p> 0.05). Results 
are shown in Table 5. To further analyze variables in the 
univariate analysis (Table 5), a multivariate regression 
analysis was performed. Considering multi-collinearity 
in the multivariate analysis, it was found that mechanical 
ventilation was a confounding factor (p> 0.05), while 
the APACHE II score, CVC catheterization, and the 
use of broad-spectrum antibiotics were closely related 
to C.  parapsilosis bloodstream infections (p=0.001; 









Neutropenia 0 (0.0) 3 (2.8) 0 (0.0) > 0.05
Positive G test 25 (39.7) 39 (37.5) 38 (38.0) > 0.05
MODS 20 (31.7) 35 (33.7) 41 (41.0) > 0.05
Coinfection 28 (44.4) 38 (36.5) 39 (39.0) > 0.05
*Values for all variables are given in percentages of patients; #All Candida species other than C. albicans or C. parapsilosis included 
46 C. tropicalis, 22 C. glabrata, 23 C. guilliermondii, 5 C. krusei and 4 C. lusitaniae; MODS = Multiple organ dysfunction syndrome.
Table 5 - Risk factors for C. parapsilosis bloodstream infections after single parameter analysis. 
B Wald OR (95% CI) P
Age (year) (Mean ± SD) -0.015 2.184 0.985 (0.965-1.005) 0.139
Gender (Male) -0.275 0.733 0.760 (0.405-1.425) 0.392
Underlying comorbidities -0.277 0.687 0.758 (0.394-1.459) 0.407
APACHE II Scores 0.164 19.157 1.179 (1.095-1.268) 0.000
ICU length of stay (days) -0.008 0.156 0.992 (0.952-1.033) 0.693
Mortality 0.386 0.478 1.471 (0.493-4.393) 0.498
Central venous catheter 1.585 21.178 4.881 (2.485-9.588) 0.000
Internal jugular catheter -0.067 0.024 0.935 (0.395-2.211) 0.878
Subclavian vein catheterization 1.409 8.650 4.091 (1.600-10.462) 0.003
Femoral vein catheterization 1.037 6.196 2.820 (1.247-6.739) 0.013
Basilic vein catheterization 1.115 1.014 3.050 (0.348-26.727) 0.314
Broad-spectrum antibiotics 1.141 11.468 3.129 (1.617-6.056) 0.001
Steroids 0.172 0.038 1.188 (0.211-6.683) 0.845
CVC duration > 5 days 0.944 6.801 2.571 (1.264-5.229) 0.009
Total parenteral nutrition > 3 days 1.449 18.074 4.260 (2.184-8.309) 0.000
Mechanical ventilation 0.715 4.768 2.044 (1.077-3.880) 0.029
Continuous renal replacement therapy 0.148 0.128 1.159 (0.517-2.601) 0.720
Abdominal surgeries -0.005 0.000 0.995 (0.486-2.040) 0.989
Positive G test -0.134 0.167 0.875 (0.459-1.664) 0.683
MODS 0.049 0.020 1.050 (0.538-2.051) 0.886
Coinfection -0.267 0.668 0.766 (0.404-1.452) 0.414
B = Coefficient estimates; Wald: Chi-square value; OR: Odds ratio; CI = Confidence interval; APACHE = Acute Physiology and 
Chronic Health Evaluation; CVC = Central venous catheter.
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0.001; 0.040), with OR values of 1.159, 3.913 and 2.217, 
respectively. Results are shown in Table 6.
Treatment and prognosis
The main treatment measures included removal of 
the central venous catheters and antifungal therapy. 
Echinocandins (micafungin, caspofungin) were used 
as previously recommended3. In two cases, the central 
catheters could not be removed or replaced. There were 
25 deaths (five in C. albicans group, 12 in C. parapsilosis 
group, and eight in the other non-C.  albicans groups). 
There was a statistical difference in mortality between the 
C. parapsilosis group and the other non-C. albicans species 
group (p=0.046), while there were no statistical differences 
in ICU length of stay between the groups. These results are 
shown in Table 2. 
DISCUSSION
Candida bloodstream infections are still serious 
nosocomial infections worldwide and are the third or 
fourth causes of healthcare-related bloodstream infections8. 
C.  albicans has been regarded as the main pathogenic 
fungus, however, in recent years, non-C. albicans species 
have gradually become the main pathogen of hospital-
acquired candidemia11,12. Studies have shown that the 
most frequently implicated risk factors of invasive 
candidemia include the use of broad-spectrum antibiotics, 
immunossupressant agents (glucocorticosteroids, chemo-
therapeutic agents, and immunomodulators), neutropenia, 
use of central venous catheters, total parenteral nutrition, 
renal replacement therapy and use of implantable prosthetic 
devices18,19. A number of studies have shown that the rate 
of C. parapsilosis isolation from blood samples or venous 
catheter implants is second to or higher than the rate of 
C.  albicans isolation from the same sources20,21. In our 
study, a total of 267 patients with candidemia were included. 
Among them, C.  parapsilosis accounted for 38.95% 
(104 cases) of candidemia cases, while the proportion 
of C.  albicans was 23.60% (63 cases) and of other 
non-C. albicans species was 37.45% (100 cases) (Table 1). 
To our surprise, the proportion of candidemia attributed to 
C. parapsilosis was even higher than the one of C. albicans 
during our study period, indicating that non-C. albicans 
species are becoming the most common cause of Candida 
bloodstream infections, which is consistent with data of 
previous studies11,12,21,22.
Several studies6,8 have shown that the occurrence of 
candidemia is associated with increasing length of hospital 
stay and medical costs. Almirante et al.22 found that the 
early and overall mortality of patients with C. parapsilosis 
candidemia was lower than those of C. albicans (6% vs 25%, 
7 days; 23% vs 43%, overall; p< 0.01). In our study, we 
compared candidemia caused by different species andthe 
results indicated that there was no significant differences 
in terms of mortality and ICU length of stay compared to 
candidemia caused by C. parapsilosis and C. albicans. 
Regarding risk factors, an observational study in 
Europe concluded that catheter implantation, use of broad-
spectrum antibiotic, total parenteral nutrition, abdominal 
surgeries, glucocorticoid therapy, tumors, organ transplants, 
neutropenia and previous Candida colonization are high-
risk factors for C.  parapsilosis candidemia22. Our study 
showed that APACHE II score, CVC catheterization and 
use of broad-spectrum antibiotics were independent risk 
factors for C. parapsilosis candidemia (Table 6). 
APACHE II is a severity-of-disease classification system 
proposed by Knaus et al.23 that has been widely used in 
emergency and critical care medicine. It is determined 
within 24 h of admission to an ICU, with higher scores 
corresponding to more severe disease and a higher risk 
of death. In our study, the average APACHE II score of 
C. parapsilosis candidemia patients was above 25, which 
was significantly higher than the one of candidemia patients 
caused by other Candida species (Table 2). We can also 
imply that C. parapsilosis candidemia patients were in more 
severe conditions when admitted to emergency department.
It is reported that approximately 80% of patients 
with non-neutropenic candidemia originated from the 
presence of intravascular catheters, such as a central 
venous catheter, a hemodialysis catheter, a PICC or an 
implantation port. Clinically useful biological materials 
can easily favor Candida colonization and biofilm 
Table 6 - Risk factors in the multivariate analysis of C. parapsilosis bloodstream infections. 
B Wald OR (95% CI) P
APACHE II Scores 0.148 11.969 1.159 (1.066- 1.261) 0.001
Central venous catheter 1.364 11.978 3.913 (1.807- 8.474) 0.001
Broad-spectrum antibiotics 0.796 4.233 2.217 (1.038- 4.734) 0.040
B = Coefficient estimates; Wald = Chi-square value; OR = Odds ratio; CI = Confidence interval; APACHE = Acute Physiology and 
Chronic Health Evaluation.
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formation, and cause related bloodstream infections24-27. 
In our study, patients with C.  parapsilosis candidemia 
showed a higher rate of CVC compared with those of other 
Candida species (Table 3). An analysis of 393 cases of 
Candida spp. bloodstream infections in Switzerland, from 
2005 to 2006, showed that the positive rate of biofilms 
in cases caused by non-C. albicans species (88.7%) was 
significantly higher than that of C.  albicans (40.3%), 
while in the C.  parapsilosis group the rate of biofilms 
reached 66.7%. This study indicated that the ability of 
Candida to adhere to the surface of the conduct to form 
a biofilm was highly strain-dependent. C.  parapsilosis 
isolated from different locations have different biofilm-
forming capabilities, which was the strongest when the 
isolates were from bloodstream cultures28. Studies by 
Branchini et al.14 found that C. parapsilosis can proliferate 
in high-concentration glucose conditions and form a 
biofilm on the prosthetic material. The mucus production 
by C.  parapsilosis helps it to fix on plastic catheters, 
and the biofilm formation is related to the colonization 
ability of C.  parapsilosis placed on the central venous 
catheter, and has been considered as a virulence factor 
for C. parapsilosis candidemia. A Costa Rican clinical 
study found a strong association between C. parapsilosis 
candidemia and central venous catheterization and total 
parenteral nutrition20. In addition, the colonization and 
C. parapsilosis infection depend on its ability to adhere to 
host cell tissues, especially mucosal epithelia. As adhesion 
can promote the destruction of adjacent host cells by 
Candida, this adhesion in C. parapsilosis may be related 
to the presence of hydrophobic molecules on the surface 
of Candida spp.29.
Our results indicated that the administration of broad-
spectrum antibiotics was another independent risk factors 
for C.  parapsilosis candidemia (Table 6). We know 
that empiric broad-spectrum therapy with one or more 
intravenous antimicrobials to cover all likely pathogens 
should be started immediately in patients presenting with 
sepsis or septic shock30. In the updated Surviving Sepsis 
Campaign (SSC) bundle of care31, which have combined 
the 3-h and 6-h bundles into a single “hour-1 bundle” 
recommendations such as obtaining blood cultures prior 
to administration of antibiotics and administration of 
broad-spectrum antibiotics in 1 h should be accomplished 
within“hour-1 bundle”. Once the pathogen identification 
and its sensitivities are established, empiric antimicrobial 
therapy should be narrowed or discontinued if infection is 
subsequently proven not to exist. The link between early 
administration of broad-spectrum antibiotics for suspected 
infection and antibiotic stewardship remains an essential 
aspect of high-quality sepsis management. 
In short, this study analyzed the demographic 
characteristics, underlying comorbidities, clinical 
interventions and laboratory data of patients with candidemia 
indicating that among the pathogens that cause candidemia 
in ICU, C. parapsilosis among the non-C. albicans species 
is becoming dominant. Moreover, the results showed that 
APACHE II score, CVC catheterization and use of broad-
spectrum antibiotics were independent risk factors for 
C. parapsilosis candidemia. Because this is a monocentric 
study, further multicenter studies placed in different 
geographical regions should perform studies on candidemia 
in ICU patients to better define the epidemiology and 
pathogenesis of candidemia, helping intensive care 
specialists to assess the distribution and trends in their 
patients with clinically suspected candidemia.
CONCLUSION
In the ICU patients with candidemia, C. parapsilosis is 
becoming the main pathogen among NCAC candidemia. 
APACHE II scores, central venous catheterization and 
use of broad-spectrum antibiotics were independent risk 
factors for the occurrence of C. parapsilosis candidemia, 
which may provide data to support the early anti-fungal 
therapy. There are several limitations in the present study. 
First of all, this is a retrospective clinical study which is 
frequently used for severe nosocomial infections with low 
incidence rates that may need very large sample sizes for 
more accurate outcome analysis. Secondly, the sample in 
this study was selected over 6 years, so that the testing 
procedures may have varied over time. However, in our 
study, we have not detected any variation over time. Finally, 
this is a monocentric study and the findings are focused 
on C. parapsilosis candidemia, so that the results can be 
extrapolated but with caution. Further multicenter studies 
can better define the epidemiology and pathogenesis of 
C. parapsilosis candidemia.
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